Scarica l'app Stockscreener
6.145
4.66%
0.245
Precedente Chiudi:
$5.90
Aprire:
$6
Volume 24 ore:
1.53M
Relative Volume:
0.98
Capitalizzazione di mercato:
$629.44M
Reddito:
-
Utile/perdita netta:
$-167.48M
Rapporto P/E:
-3.1513
EPS:
-1.95
Flusso di cassa netto:
$-197.47M
1 W Prestazione:
-10.25%
1M Prestazione:
-9.06%
6M Prestazione:
-49.09%
1 anno Prestazione:
-54.23%
Intervallo 1D:
$5.945
$6.19
Intervallo di 1 settimana:
$5.635
$6.245
Portata 52W:
$5.635
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Confronta DAWN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.145 | 624.83M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.27 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.36 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.35 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.80 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
Day One Biopharmaceuticals Receives Bullish Ratings from Analysts Amid Promising Growth Prospects - AInvest
Day One Biopharmaceutical Stock Price, Quotes and Forecasts | NASDAQ:DAWN - Benzinga
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
Needham Maintains Buy Rating on Day One Biopharmaceutical, Lowers Price Target to $16.00. - AInvest
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $16 to $26 - 富途牛牛
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals - TipRanks
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest
Day One Biopharmaceuticals shares fall 14.24% premarket after Q2 2025 earnings call. - AInvest
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN
Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest
Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Biopharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Day One Biopharma Reports Strong Q2 2025 Growth - TipRanks
Day One Biopharmaceuticals Reports Q2 2025 Financial Results and Strategic Appointments. - AInvest
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory - AInvest
Day One Biopharmaceuticals: Scaling OJEMDA Revenue While Strengthening R&D and Financial Discipline - AInvest
Transcript : Day One Biopharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Day One Biopharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Day One Biopharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c) - TipRanks
Day One Biopharmaceuticals Q2 Revenue Rises Amid Leadership Changes and Earnings Calls - AInvest
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals Reports Q2 2025 Financial Results, Expects $140-150M in OJEMDA Net Product Revenue for FY25 - AInvest
What are analysts’ price targets for Day One Biopharmaceuticals Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stock - Jammu Links News
Is it the right time to buy Day One Biopharmaceuticals Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastCapitalize on emerging trends for profits - Jammu Links News
Why is Day One Biopharmaceuticals Inc. stock attracting strong analyst attentionFree Investment Community - Jammu Links News
How does Day One Biopharmaceuticals Inc. generate profit in a changing economyTremendous growth opportunities - Jammu Links News
Is Day One Biopharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Unbelievable profit margins - Jammu Links News
What are the technical indicators suggesting about Day One Biopharmaceuticals Inc.Build a portfolio that outperforms consistently - Jammu Links News
Does Day One Biopharmaceuticals Inc. stock perform well during market downturnsPhenomenal trading returns - Jammu Links News
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetInvest smarter with cutting-edge analytics - Jammu Links News
What makes Day One Biopharmaceuticals Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - 富途牛牛
Published on: 2025-07-30 22:40:17 - Newser
Can Day One Biopharmaceuticals Inc. recover in the next quarterWeekly Stock Opportunity Radar Scanner Activated - metal.it
How Day One Biopharmaceuticals Inc. stock performs during market volatilityNeural Model for Stock Price Movement - Newser
Published on: 2025-07-30 04:25:27 - Newser
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Day One Biopharmaceuticals Inc Azioni (DAWN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
May 16 '25 |
Sale |
6.26 |
4,552 |
28,486 |
47,136 |
| York Charles N II | COO, CFO AND SECRETARY |
May 16 '25 |
Sale |
6.26 |
4,282 |
26,796 |
265,231 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '25 |
Sale |
6.26 |
13,964 |
87,385 |
145,737 |
0.47%
2.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):